Brief: Galecto To Present Topline Data From Clinical Trial Showing GB1211 Reduced Signs Of Liver Impairment At AASLD's The Liver Meeting 2022
31/10/2022 12:59
Oct 31 (Reuters) - Galecto Inc GLTO.O :
* GALECTO TO PRESENT TOPLINE DATA FROM GULLIVER-2 CLINICAL
TRIAL
SHOWING GB1211 REDUCED SIGNS OF LIVER IMPAIRMENT AT AASLD’S THE
LIVER MEETING® 2022
Source text for Eikon: ID:nGNX2fPsR4
Further company coverage: GLTO.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Damora Therapeutics
See all newsUS RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
U.S. RESEARCH ROUNDUP-Blackstone, Hartford Insurance, Zevra Therapeutics
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology
Brief: Damora Therapeutics Reports First Quarter 2026 Financial Results
Brief: Damora Therapeutics: Lori Firmani To Cease Serving As CFO Effective May 1, 2026 - SEC Filing